These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 37826924)
1. Effects of Antihypertensive Agents on the Clinical Outcome of Hospitalized COVID-19 Patients Concomitant with Hypertension: A Systematic Review and Meta-Analysis. Liu J; Huang L; Wei W; Bai Y; Chang E; Leng Y Heart Lung; 2024; 63():78-85. PubMed ID: 37826924 [TBL] [Abstract][Full Text] [Related]
2. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis. Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513 [TBL] [Abstract][Full Text] [Related]
3. Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis. Liu Q; Fu W; Zhu CJ; Ding ZH; Dong BB; Sun BQ; Chen RC BMC Infect Dis; 2023 Jan; 23(1):53. PubMed ID: 36694122 [TBL] [Abstract][Full Text] [Related]
4. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. COVID-19 RISk and Treatments (CORIST) Collaboration Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048 [TBL] [Abstract][Full Text] [Related]
5. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers. Choksi TT; Zhang H; Chen T; Malhotra N Am J Nephrol; 2021; 52(3):250-260. PubMed ID: 33827074 [TBL] [Abstract][Full Text] [Related]
6. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265 [TBL] [Abstract][Full Text] [Related]
7. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877 [TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
9. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202 [TBL] [Abstract][Full Text] [Related]
10. Does taking an angiotensin inhibitor increase the risk for COVID-19? - a systematic review and meta-analysis. Ma Z; Wang MP; Liu L; Yu S; Wu TR; Zhao L; Zhang YP; Liang HF; Yang XC Aging (Albany NY); 2021 Apr; 13(8):10853-10865. PubMed ID: 33886504 [TBL] [Abstract][Full Text] [Related]
11. ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis. Zhang X; Yu J; Pan LY; Jiang HY Pharmacol Res; 2020 Aug; 158():104927. PubMed ID: 32422341 [TBL] [Abstract][Full Text] [Related]
12. Impact of Treatment with Renin-Angiotensin System Inhibitors on Clinical Outcomes in Hypertensive Patients Hospitalized with COVID-19. Negreira-Caamaño M; Piqueras-Flores J; Martínez-DelRio J; Nieto-Sandoval-Martin-DeLaSierra P; Aguila-Gordo D; Mateo-Gomez C; Salas-Bravo D; Rodriguez-Martinez M; Negreira-Caamaño M High Blood Press Cardiovasc Prev; 2020 Dec; 27(6):561-568. PubMed ID: 32949380 [TBL] [Abstract][Full Text] [Related]
13. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Li EC; Heran BS; Wright JM Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009096. PubMed ID: 25148386 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients. Zhang L; Zeng X; Fu P; Wu HM Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009120. PubMed ID: 24953826 [TBL] [Abstract][Full Text] [Related]
17. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Pranata R; Permana H; Huang I; Lim MA; Soetedjo NNM; Supriyadi R; Soeroto AY; Alkatiri AA; Firman D; Lukito AA Diabetes Metab Syndr; 2020; 14(5):983-990. PubMed ID: 32615377 [TBL] [Abstract][Full Text] [Related]
18. [Association of hypertension and antihypertensive agents and the severity of COVID-19 pneumonia. A monocentric French prospective study]. Georges JL; Cochet H; Roger G; Ben Jemaa H; Soltani J; Azowa JB; Mamou R; Gilles F; Saba J; Prevot A; Pasqualini M; Monguillon V; De Tournemire M; Bertrand A; Koukabi-Fradelizi M; Beressi JP; Livarek B Ann Cardiol Angeiol (Paris); 2020 Nov; 69(5):247-254. PubMed ID: 33039120 [TBL] [Abstract][Full Text] [Related]
19. Discontinuation of Antihypertensive Drug Use Compared to Continuation in COVID-19 Patients: A Systematic Review with Meta-analysis and Trial Sequential Analysis. Chambergo-Michilot D; Runzer-Colmenares FM; Segura-Saldaña PA High Blood Press Cardiovasc Prev; 2023 May; 30(3):265-279. PubMed ID: 37171528 [TBL] [Abstract][Full Text] [Related]
20. Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis. Ren L; Yu S; Xu W; Overton JL; Chiamvimonvat N; Thai PN J Cardiol; 2021 May; 77(5):482-491. PubMed ID: 33168337 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]